Log in to your Inderes Free account to see all free content on this page.

OncoZenge

5.71 SEK

-1.55 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-1.55 %

-1.72 %

-15.53 %

-13.09 %

-9.08 %

-9.37 %

-6.39 %

-48.33 %

-53.34 %

OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Market cap

80.21M SEK

Turnover

63.62K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

20.5.

2026

Interim report Q1'26

27.5.

2026

General meeting '26

27.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Press release2/26/2026, 2:29 PM

Redeye: OncoZenge (Q4 review): Final preparations ahead of phase III

Regulatory press release2/26/2026, 7:00 AM

OncoZenge AB Year-end Report January 1 – December 31, 2025

Press release2/12/2026, 9:22 AM

OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release2/4/2026, 8:40 AM

OncoZenge AB Unveils Key Insights from UCLA Patient Engagement Study on Oral Mucositis Pain Management

Press release2/2/2026, 8:30 AM

OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer

Press release1/30/2026, 2:40 PM

OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge™ Technology Batch, Advancing Toward Clinical Trials

Regulatory press release1/22/2026, 6:19 PM

OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds

Regulatory press release1/21/2026, 4:32 PM

OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact

Press release12/19/2025, 11:52 AM

BioStock: OncoZenge advances BupiZenge with CTA submission and 9,1 MSEK funding tranche

Regulatory press release12/19/2025, 7:50 AM

OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement

Press release12/18/2025, 4:23 PM

OncoZenge Submits Clinical Trial Application for Pivotal Phase III Trial (BZ003) of BupiZenge™

Press release12/11/2025, 9:45 AM

BioStock: Co-inventor Dr. Torben Mogensen joins OncoZenge advisory board ahead of phase III

Press release12/5/2025, 11:52 AM

BioStock: OncoZenge and Molteni expand partnership for BupiZenge

Press release12/3/2025, 7:45 AM

OncoZenge and Molteni expand partnership: Molteni to assume commercial manufacturing of BupiZenge™ for Europe

Press release11/17/2025, 9:00 AM

OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge™

Press release10/31/2025, 9:41 AM

BioStock: OncoZenge gearing up for phase III after a strong quarter

Press release10/30/2025, 1:52 PM

Redeye: OncoZenge (Q3 review) - Gearing up for a transformative 2026

Regulatory press release10/30/2025, 7:00 AM

OncoZenge AB Interim Report January 1 – September 30, 2025

Press release10/13/2025, 8:20 AM

BioStock: UCLA study provides OncoZenge with patient insights ahead of phase III

Press release10/9/2025, 6:45 AM

OncoZenge AB: First Patient Enrolled in UCLA Patient Engagement Study

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.